natgillin/translations-raw huggingface dataset:
Two Phase III, randomised, double-blind, placebo-controlled studies RAISE (TRA102537) and TRA100773B and two open-label studies REPEAT (TRA108057) and EXTEND (TRA105325) evaluated the safety and efficacy of eltrombopag in adult patients with previously treated chronic ITP.
Varnost in učinkovitost uporabe eltrombopaga pri predhodno že zdravljenih odraslih bolnikih s kronično ITP je bila ovrednotena z dvema randomiziranima, dvojno slepima, s placebom nadzorovanima študijama III. faze RAISE (TRA102537) in TRA100773B ter dvema odprtima študijama REPEAT (TRA108057) in EXTEND (TRA105325).
Two phase III, randomized, double-blind, placebo controlled confirmatory studies, (MS-F203 and MS-F204) have been performed.
V fazi III kliničnega preizkušanja zdravila so opravili dve randomizirani, dvojno slepi, s placebom kontrolirani potrditveni študiji (MS-F203 in MS-F204).
Two phase-III clinical trials were completed in a total of 851 postmenopausal women with advanced breast cancer who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease.
Zaključeni sta bili dve klinični preskušanji III. faze na skupno 851 ženskah po menopavzi z napredovalim rakom dojke, pri katerih se je bolezen ponovila med ali po adjuvantnem endokrinem zdravljenju ali pa je prišlo do poslabšanja bolezni po endokrinem zdravljenju napredovale bolezni.
Two piece capsules with a white to off-white opaque body and white to off-white opaque cap imprinted with “PFD 267 mg” in brown ink and containing a white to pale yellow powder.
Dvodelne kapsule z belim do belkastim neprozornim spodnjim delom in belim do belkastim neprozornim zgornjim delom, na katerem je z rjavim črnilom natisnjen napis „PFD 267 mg“, vsebujejo pa bel do bledorumen prašek.
Two pivotal trials (SP512 Part I and SP513 Part I) investigating the effectiveness of rotigotine in the treatment of the signs and symptoms of idiopathic Parkinson’s disease were conducted in patients who were not receiving concomitant dopamine agonist therapy and were either L-dopa naïve or previous L-dopa treatment was ≤ 6 months.
Dve ključni preskušanji (SP512 del I in SP513 del I), pri katerih so preučevali učinkovitost rotigotina pri zdravljenju znakov in simptomov idiopatične Parkinsonove bolezni, so opravili na bolnikih, ki niso prejemali sočasnega zdravljenja z agonistom dopamina in ki bodisi niso nikoli prejemali L-dope ali katerih predhodno zdravljenje z L-dopo je trajalo ≤ 6 mesecev.
Two pivotal trials (SP512 Part I and SP513 Part I) investigating the effectiveness of rotigotine in the treatment of the signs and symptoms of idiopathic Parkinson’s disease were conducted in patients who were not receiving concomitant dopamine agonist therapy and were either L-dopa naïve or previous L-dopa treatment was ≤ 6 months.
Dve pivotni preskušanji (SP512 del I in SP513 del I), pri katerih so preučevali učinkovitost rotigotina pri zdravljenju znakov in simptomov idiopatične Parkinsonove bolezni, so opravili na bolnikih, ki niso prejemali sočasnega zdravljenja z agonistom dopamina in ki bodisi niso nikoli prejemali L-dope ali katerih predhodno zdravljenje z L-dopo je trajalo ≤ 6 mesecev.
Two pivotal, open label, uncontrolled, multicentre studies have been conducted, one exclusively in previously untreated patients (n=67), and the other in previously untreated patients (n=63) and in children previously treated with somatropin (n=9).
Izvedeni sta bili dve ključni, odprti, nenadzorovani multicentrični študiji, ena izključno pri predhodno nezdravljenih bolnikih (n=67), druga pa pri predhodno nezdravljenih bolnikih (n=63) in pri otrocih, ki so se predhodno zdravili s somatropinom (n=9).
Two polyethylene/polypropylene measuring syringes, a 1 ml and 5 ml syringe, are supplied with each bottle to ensure accurate dosing of small and large dogs.
K vsaki steklenički sta priloženi dve polietilenski/polipropilenski merilni brizgalki po 1 ml in 5 ml, ki omogočata natančno odmerjanje za večje in manjše pse.
Two polyethylene/polypropylene measuring syringes, a 1 ml and a 5 ml syringe, are supplied with each bottle to ensure accurate dosing of small and large dogs.
K vsaki steklenički sta priloženi dve polietilenski/polipropilenski merilni brizgalki po 1 ml in 5 ml, ki omogočata natančno odmerjanje za večje in manjše pse.
Two polyvinyl chloride/aluminum blisters each containing 15 soft capsules are contained in a wallet.
Dva pretisna omota iz polivinilklorida/aluminija, od katerih vsak vsebuje po 15 mehkih kapsul, v zloženki.
Two pre-filled pens are available.
Na voljo sta dva napolnjena injekcijska peresnika.
two pre-filled syringes of solution, and two alcohol wipes (for cleansing the areas chosen for injection).
dve napolnjeni injekcijski brizgi z raztopino, in dva alkoholna zloženca (za čiščenje izbranega mesta injiciranja).
two pre-filled syringes with needle guard of solution, and two alcohol wipes (for cleansing the areas chosen for injection).
dve napolnjeni injekcijski brizgi z varovalom za iglo z raztopino, in dva alkoholna zloženca (za čiščenje izbranega mesta injiciranja).
two pump actuations
dva pritiska navzdol
two pump actuations.
dva pritiska navzdol
Two randomised phase 3 studies (COMFORT-I and COMFORT-II) were conducted in patients with MF (primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis).
Pri bolnikih z mielofibrozo (s primarno mielofibrozo, z mielofibrozo pri pravi policitemiji ali z mielofibrozo pri esencialni trombocitemiji) so izvedli dve randomizirani študiji faze 3 (COMFORT-I in COMFORT-II).
Two randomised, controlled prophylaxis studies were conducted among patients at high risk for developing invasive fungal infections.
Opravljeni sta bili dve randomizirani, kontrolirani študiji profilakse pri bolnikih z velikim tveganjem za nastanek invazivnih glivičnih okužb.
Two randomised, controlled prophylaxis studies were conducted among patients at high risk for developing invasive fungal infections.
Opravljeni sta bili dve randomizirani, kontrolirani študiji profilakse pri bolnikih z velikim tveganjem za pojav invazivnih glivnih okužb.
Two randomised, double-blind, multi-centre, placebo-controlled studies have been conducted in 122 (study AC-052-401 [RAPIDS-1]) and 190 (study AC-052-331 [RAPIDS-2]) adult patients with systemic sclerosis and digital ulcer disease (either ongoing digital ulcers or a history of digital ulcers within the previous year).
Opravili so dve randomizirani dvojno slepi multicentrični s placebom nadzorovani študiji in sicer pri 122 (študija AC-052-401 [RAPIDS-1]) in 190 (študija AC-052-331 [RAPIDS-2]) odraslih bolnikih s sistemsko sklerozo in boleznijo razjed prstov (bodisi nastajajočimi razjedami prstov ali z anamnezo razjed prstov v prejšnjem letu).
Two randomised, double-blind, multi-centre, placebo-controlled studies have been conducted in 32 (study AC-052-351) and 213 (study AC-052-352 [BREATHE-1]) adult patients with WHO functional class III– IV pulmonary arterial hypertension (primary pulmonary hypertension or pulmonary hypertension secondary mainly to scleroderma).
Opravili so dve randomizirani dvojno slepi multicentrični s placebom nadzorovani študiji in sicer pri 32 (študija AC-052-351) in 213 (študija AC-052-352 [BREATHE-1]) odraslih bolnikih s pljučno arterijsko hipertenzijo funkcijskega razreda III-IV po klasifikaciji Svetovne zdravstvene organizacije (primarna pljučna hipertenzija ali sekundarna pljučna hipertenzija predvsem zaradi skleroderme).
Two randomised, double-blind, multi-centre, placebo-controlled studies have been conducted in 32 (study AC-052-351) and 213 (study AC-052-352 [BREATHE-1]) adult patients with WHO functional class III–IV pulmonary arterial hypertension (primary pulmonary hypertension or pulmonary hypertension secondary mainly to scleroderma).
Opravili so dve randomizirani dvojno slepi multicentrični s placebom nadzorovani študiji in sicer pri 32 (študija AC-052-351) in 213 (študija AC-052-352 [BREATHE-1]) odraslih bolnikih s pljučno arterijsko hipertenzijo funkcijskega razreda III-IV po klasifikaciji Svetovne zdravstvene organizacije (primarna pljučna hipertenzija ali sekundarna pljučna hipertenzija predvsem zaradi skleroderme).
Two randomised, double-blind, placebo-controlled pivotal phase III studies and a phase II study contribute to the safety profile of Votubia.
Varnostni profil zdravila Votubia je bil ugotovljen v dveh randomiziranih, dvojno slepih, s placebom kontroliranih osrednjih študijah faze III in študiji faze II.
Two randomised, double-blind, placebo-controlled studies (LEVP 2005-1/A and LEVP 2005-1/B) and data from two open-label studies (LEVP 2006-1 and LEVP 2006-4) demonstrated the efficacy of Cinryze for the treatment and prevention of angioedema attacks in subjects with C1 inhibitor deficiency.
Dve randomizirani, dvojno slepi, s placebom kontrolirani študiji (LEVP 2005-1/A in LEVP 2005-1/B) in podatki iz dveh odprtih študij (LEVP 2006-1 in LEVP 2006-4) so dokazali učinkovitost zdravila Cinryze za zdravljenje in preprečevanje napadov angioedema pri osebah s pomanjkanjem zaviralca C1.
Two randomised, open-label studies were conducted to evaluate the efficacy and safety of Empliciti (elotuzumab) in adult patients with multiple myeloma who have received one or more prior therapies.
Učinkovitost in varnost zdravila Empliciti (elotuzumab) pri odraslih bolnikih z multiplim mielomom, ki so se predhodno zdravili z eno ali več oblikami zdravljenja, so vrednotili v dveh randomiziranih odprtih študijah.
Two randomised, open-label, multicenter Phase III trials (IFM-2005-01, MMY-3010) were conducted to demonstrate the safety and efficacy of VELCADE in dual and triple combinations with other chemotherapeutic agents, as induction therapy prior to stem cell transplantation in patients with previously untreated multiple myeloma.
Za potrditev varnosti in učinkovitosti uvajalnega zdravljenja z zdravilom VELCADE v kombinacijah z dvema ali tremi kemoterapevtskimi učinkovinami, pred presaditvijo krvotvornih matičnih celic pri bolnikih s še nezdravljenim diseminiranim plazmocitomom so izvedli dve randomizirani, odprti, multicentrični preskušanji faze III (IFM-2005-01, MMY-3010).
Two randomized, parallel group, double-blind studies were performed in patients previously treated with anticagulation therapy.
Opravljeni sta bili dve dvojno slepi študiji s paralelnimi skupinami naključno izbranih bolnikov, ki so predhodno že jemali antikoagulacijska zdravila.
Two samples are collected
Zdravnik vzame dva vzorca
Two serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL are recommended; the second test should be performed 8 – 10 days after the first one and immediately before starting mycophenolate mofetil.
Priporočljiva sta dva serumska ali urinska testa nosečnosti z občutljivostjo najmanj 25 mi.e./ml, drugi test mora biti opravljen 8–10 dni po prvem in nemudoma pred začetkom zdravljenja z mofetilmikofenolatom.
Two serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL are recommended; the second test should be performed 8-10 days after the first one and immediately before starting mycophenolate mofetil.
Priporočljiva sta dva serumska ali urinska testa nosečnosti z občutljivostjo najmanj 25 mi.e./ml, drugi test mora biti opravljen 8 – 10 dni po prvem in nemudoma pred začetkom zdravljenja z mofetilmikofenolatom.
Two serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL are recommended; the second test should be performed 8-10°days after the first one and immediately before starting mycophenolate mofetil.
Priporočljiva sta dva serumska ali urinska testa nosečnosti z občutljivostjo najmanj 25 mi.e./ml, drugi test mora biti opravljen 8 – 10 dni po prvem in nemudoma pred začetkom zdravljenja z mofetilmikofenolatom.
Two short-term studies, 95-001 (malignant pain) and 96-002 (non malignant pain), involving 366 patients, demonstrated the efficacy of IT ziconotide in severe chronic pain using the percent change in Visual Analog Scale of Pain Intensity (VASPI) as the primary efficacy measure.
Dve kratkoročni študiji, 95-001 (maligna bolečina) in 96-002 (nemaligna bolečina) pri 366 bolnikih sta demonstrirali učinkovitost intratekalno apliciranega zikonotida ob močni kronični bolečini in sta kot primarno merilo učinkovitosti uporabili odstotno spremembo na vizualno analogni skali intenzitete bolečine (VASPI, Visual Analog Scale of Pain Intensity).
Two sided 95% CI b
Dvostranski 95 % IZ b
two SIFROL 0.26 mg prolonged-release tablets.
dve SIFROL 0,26 mg tableti s podaljšanim sproščanjem
Two single-arm, open-label clinical studies, AURAex (Phase II Extension cohort, (n=201)) and AURA2 (n=210) were conducted in patients with EGFR T790M mutation-positive lung cancer who have progressed on prior systemic therapy, including an EGFR TKI active substance.
Pri bolnikih z rakom pljuč in mutacijo T790M EGFR, ki jim je bolezen napredovala med predhodnim sistemskim zdravljenjem (vključno z učinkovino EGFR TKI), so izvedli dve odprti klinični študiji z enim samim krakom (eno samo skupino): AURAex (kohorta v podaljšani študiji II. faze (n = 201)) in AURA2 (n = 210).
Two small bowls
dve manjši posodi
Two small bowls
dve manjši posodi,
Two small bowls (use separate pairs of bowls for each child)
dve manjši posodi (za vsakega otroka uporabljajte ločen par posod)
Two small bowls (use separate pairs of bowls for each child)
dve manjši posodi (za vsakega otroka uporabljajte ločen par posod),
Two smaller studies (238 patients) have also looked at the effectiveness of Xeloda after failure of treatment with taxanes and anthracyclines.
V dveh manjših študijah (z 238 bolniki) so prav tako proučevali učinkovitost zdravila Xeloda po neuspešnem zdravljenju s taksani in antraciklini.
Two smaller studies comparing Leganto with ropinirole were completed after the medicine’s authorisation.
Po odobritvi zdravila sta bili izvedeni še dve manjši študiji, v katerih so zdravilo Leganto primerjali z ropinirolom.
Two smaller studies comparing Neupro with ropinirole were completed after the medicine’s authorisation.
Po odobritvi zdravila sta bili izvedeni še dve manjši študiji, v katerih so zdravilo Neupro primerjali z ropinirolom.
Two sterile 3 ml disposable polypropylene syringes with stainless steel needles attached.
dve sterilni 3-ml polipropilenski injekcijski brizgi za enkratno uporabo s pritrjeno iglo iz nerjavečega jekla
Two sterile syringes, one with needle for reconstitution Three hypodermic safety needles
Dve sterilni injekcijski brizgi, ena z iglo za rekonstitucijo Tri hipodermične varnostne igle
two stripes in black ink on the cap and “T 250 mg” in black ink on the body
dve črni progi na kapici in črn napis “T 250 mg” na telesu
two stripes in black ink on the cap and “T 250 mg” in black ink on the body
Dve črni črtici na kapici in črna oznaka “T 250 mg” na telesu kapsule
two stripes in blue ink on the cap and “T 140 mg” in blue ink on the body
dve modri progi na kapici in moder napis “T 140 mg” na telesu
two stripes in blue ink on the cap and “T 140 mg” in blue ink on the body
Dve modri črtici na kapici in modra oznaka “T 140 mg” na telesu kapsule
two stripes in green ink on the cap and “T 5 mg” in green ink on the body
dve zeleni progi na kapici in zelen napis “T 5 mg” na telesu
two stripes in green ink on the cap and “T 5 mg” in green ink on the body
Dve zeleni črtici na kapici in zelena oznaka “T 5 mg” na telesu kapsule
two stripes in orange ink on the cap and “T 20 mg” in orange ink on the body
dve oranžni progi na kapici in oranžen napis “T 20 mg” na telesu
two stripes in orange ink on the cap and “T 20 mg” in orange ink on the body
Dve oranžni črtici na kapici in oranžna oznaka “T 20 mg” na telesu kapsule
two stripes in pink ink on the cap and “T 100 mg” in pink ink on the body
Dve roza črtici na kapici in roza oznaka “T 100 mg” na telesu kapsule
two stripes in pink ink on the cap and “T 100 mg” in pink ink on the body
dve rožnati progi na kapici in rožnat napis “T 100 mg” na telesu
two stripes in red ink on the cap and “T 180 mg” in red ink on the body
dve rdeči progi na kapici in rdeč napis “T 180 mg” na telesu
two stripes in red ink on the cap and “T 180 mg” in red ink on the body
Dve rdeči črtici na kapici in rdeča oznaka “T 180 mg” na telesu kapsule
Two studies (involving 1,891 patients) compared the combination in patients whose hypertension was not adequately controlled with either 10 mg amlodipine or 160 mg valsartan.
V dveh študijah (s 1 891 bolniki) so kombinacijo primerjali pri bolnikih, pri katerih 10-miligramski odmerek amlodipina ali
Two studies assessed the effects of Invega on symptoms of mania whereas the third study assessed the effects on symptoms of depression..
V dveh od teh študij so ocenjevali učinke zdravila Invega na simptome manije, medtem ko so v tretji študiji proučevali učinke na simptome depresije.
Two studies compared different doses of Relvar Ellipta with fluticasone furoate and vilanterol given separately and placebo.
V dveh študijah so primerjali različne odmerke zdravila Relvar Ellipta z zdravilnima učinkovinama flutikazon furoat in vilanterol, ki so ju bolniki prejeli ločeno, in s placebom.
Two studies compared different doses of Revinty Ellipta with fluticasone furoate and vilanterol given separately and placebo.
V dveh študijah so primerjali različne odmerke zdravila Revinty Ellipta z zdravilnima učinkovinama flutikazon furoat in vilanterol, ki so ju bolniki prejeli ločeno, in s placebom.
two studies compared Doribax with piperacillin/tazobactam or imipenem in a total of 979 patients with nosocomial pneumonia; two studies compared Doribax with meropenem in a total of 962 patients with complicated infections in the abdomen;
v dveh študijah so zdravilo Doribax primerjali z piperacilinom/tazobaktamom ali imipenemom pri skupaj 979 bolnikih z nozokomialno pljučnico; v dveh študijah so zdravilo Doribax primerjali z meropenemom pri skupaj 962 bolnikih z zapletenimi trebušnimi okužbami;
Two studies compared the fixed-dose combination of umeclidinium and vilanterol (one corresponding to Anoro and one higher-dose combination) with vilanterol alone, umeclidinium alone and placebo (a dummy treatment).
V dveh študijah so primerjali kombinacijo umeklidinija in vilanterola s fiksnim odmerkom (ena je ustrezala zdravilu Anoro, pri drugi pa je bil odmerek višji) z vilanterolom samim, umeklidinijem samim in placebom (zdravilom brez zdravilne učinkovine).
Two studies compared two fixed-dose combinations of umeclidinium bromide and vilanterol (one corresponding to Laventair and one higher-dose combination) with vilanterol alone, umeclidinium bromide alone and placebo (a dummy treatment).
V dveh študijah so primerjali dve kombinaciji umeklidinijevega bromida in vilanterola (ena je ustrezala zdravilu Laventair, v drugi pa sta bila odmerka zdravilnih učinkovin višja) vi fiksnem odmerku s samostojnim vilanterolom, samostojnim umeklidinijevim bromidom ter placebom (zdravilom brez zdravilne učinkovine).
Two studies have been performed using either the H5N1 A/Vietnam/1203/2004 or the A/Indonesia/05/2005 vaccine.
Izvedeni sta bili dve študiji, ena s cepivom H5N1 A/Vietnam/1203/2004 in druga s cepivom A/Indonesia/05/2005.
two studies involved a total of 699 ‘treatment-experienced’ patients who were already receiving treatment for HIV infection that was not working.
v dve študiji je bilo vključenih skupno 699 predhodno zdravljenih bolnikov, ki so že prejemali zdravila za zdravljenje okužb z virusom HIV, ki pa niso bila uspešna.
Two studies involving 2,257 patients compared the effects of Aubagio with placebo in reducing the number of relapses per patient per year (called the ‘annualised relapse rate’).
V dveh študijah s 2 257 bolniki so primerjali učinke zdravila Aubagio in placeba na zmanjšanje števila recidivov na bolnika na leto (t. i. „letna stopnja recidivov“).
Two studies were carried out in chronic CML (198 and 36 patients), one was in accelerated CML (120 patients), one was in myeloid blast CML (80 patients), and one was in Ph+ ALL and lymphoid blast CML (81 patients).
V dveh študijah so proučevali KML v kroničnem obdobju (pri 198 in 36 bolnikih), v eni študiji so proučevali KML v obdobju pospešene rasti (pri 120 bolnikih), v eni KML v obdobju mieloblastne preobrazbe (pri 80 bolnikih), v zadnji študiji pa Ph-pozitivno ALL in KML v fazi limfoblastne preobrazbe (pri 81 bolnikih).
Two studies were carried out to see if TachoSil could be used as a tissue sealant.
Izvedeni sta bili dve študiji, da bi preverili, ali bi bilo mogoče zdravilo TachoSil uporabiti za zapiranje tkiva.
Two subjects randomised to tenofovir disoproxil fumarate experienced HBsAg loss by Week 240, but not seroconversion to anti-HBs.
Dva bolnika, randomizirana za dizoproksiltenofovirijev fumarat, sta imela izgubo HBsAg do 240. tedna in noben ni imel serološke konverzije anti-HBs.
Two subjects were weaned off their parenteral support while on Revestive.
Pri dveh preiskovancih je bila parenteralna prehranska podpora med zdravljenjem z zdravilom Revestive ukinjena.
Two third had a compatible timeline and half of patients developed dizziness within 7 days of administering mirabegron.
Polovica bolnikov je poročala o vrtoglavici v obdobju 7 dni po jemanju mirabegrona.
Two thousand six hundred nineteen (2619) patients received CHAMPIX 1 mg BID (titrated during the first week), 669 patients received bupropion 150 mg BID (also titrated) and 684 patients received placebo.
Dva tisoč šeststo devetnajst (2619) bolnikov je dobivalo zdravilo CHAMPIX v odmerku 1 mg dvakrat na dan (titriran med prvim tednom), 669 bolnikov je dobivalo bupropion v odmerku 150 mg dvakrat na dan (prav tako titriran), 684 bolnikov pa je dobivalo placebo.
Two times a day
dvakrat na dan
two times daily + Victrelis 800 mg
100 mg dvakrat na dan + zdravilo Victrelis 800 mg trikrat na dan)
two times daily + Victrelis 800 mg
dvakrat na dan+ zdravilo Victrelis 800 mg trikrat na dan)
Two to four hours before your dog has surgery, the recommended dose (2.6 mg fentanyl/kg bodyweight) of Recuvyra solution is applied directly on the skin between the dog’s shoulder blades.
Dve do štiri ure pred kirurško operacijo se psu nanese priporočeni odmerek (2,6 mg fentanila/kg telesne teže) raztopine Recuvyre neposredno na kožo med lopaticama.
Two to three injections of 90 µg per kg body weight administered at three-hour intervals.
Dve do tri injekcije 90 µg na kg telesne mase, aplicirane v triurnih presledkih.
Two types of peginterferon alfa (2a and 2b) were studied in the Phase 2a open label, randomised study C208 in treatment-naïve patients.
V odprti randomizirani študiji faze IIa C208 pri še nezdravljenih bolnikih so proučevali dve vrsti peginterferona alfa (2a in 2b).
Two vials of Cinryze powder must be reconstituted to make one dose (1000 Units/10 ml).
Za en odmerek (1000 enot/10 ml) morate rekonstituirati dve viali praška Cinryze.
Two vials of reconstituted Cinryze are combined for a single dose, corresponding to a concentration of 100 U/ml.
Za enkraten odmerek morate združiti dve viali rekonstituiranega zdravila Cinryze, kar ustreza koncentraciji 100 e./ml.
Two vials of reconstituted Cinryze are combined for one dose (1000 Units).
Dve viali rekonstituiranega zdravila Cinryze združite v en odmerek (1000 enot).
Two vials of reconstituted Cinryze are combined for one dose (1000 Units).
Dve viali rekonstituiranega zdravila Cinryze združite za en odmerek (1000 enot).
Two weeks later (Day 29) continue with a dose of 40 mg every week.
Čez dva tedna (29. dan) nadaljujte z odmerkom 40 mg vsak teden.
Two year data in study BM 16549
Dveletni podatki iz študije BM 16549
Two year data in study BM 16549
dveletni podatki študije BM 16549
Two year endpoint
Opazovani dogodek –dve leti
Two-dose primary series
Primarno zaporedje cepljenja z dvema odmerkoma